SEC For	m 4																			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See							TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 TOF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person [*] Ebeling Thomas							2. Issuer Name and Ticker or Trading Symbol <u>Cullinan Therapeutics, Inc.</u> [CGEM]									of Reportin able) r	g Perso	on(s) to Issu 10% Ow		
(Last) (First) (Middle) C/O CULLINAN THERAPEUTICS, INC.					05	3. Date of Earliest Transaction (Month/Day/Year) 05/23/2024									Officer (give title Other (specify below) below)					
ONE MAIN STREET, SUITE 1350															6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(Street) CAMBRIDGE MA 02142						Person														
(City)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
		Tab	le I - Nor	n-Deriv	ativ	e Se	curit	ies Ac	quire	l, Di	sposed	of, or B	enef	icially	/ Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ear)	2A. Deemed Execution Date, if any (Month/Day/Year		Cod	Transaction Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			5. Amour Securitie Beneficia Owned F	s ally ollowing	Form: (D) or	rm: Direct	7. Nature of Indirect Beneficial Ownership	
									Cod	• v	Amount	(A) (D)	or F	Price	Reported Transact (Instr. 3 a	ion(s)			Instr. 4)	
Common Stock 05/23									_	84,22		_	\$4.3		,728	<u> </u>	D			
Common Stock 05/23/									A		16,47					3,203		D		
			Fable II -								oosed of convert				Owned					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date,	Code (Ins		of Deri Sect Acq (A) o Disp of (E	umber vative urities uired or oosed 0) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Ily J	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Nu of	nount mber ares						
Stock Option (Right to Buy)	\$4.3	05/23/2024			М			84,224	(1)		10/28/2030	Common Stock	¹ 84	,224	\$0	0		D		
Stock Option (Right to Buy)	\$12.73	05/23/2024			М			16,475	06/08/2	.023	06/21/2032	Common Stock	16	5,475	\$0	0		D		

Explanation of Responses:

1. 25% of the shares vested on August 16, 2018, and the remaining shares vested in 36 equal monthly installments thereafter.

/s/ Jacquelyn Sumer, Attorney-05/23/2024

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.